Long-time Novo Nordisk bull tapped to lead Wegovy maker’s IR division

[New Nordisk]
hapabapa/iStock Editorial via Getty Images

Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) is recruiting a new head for its investor relations department: Michael Novod, a top healthcare equity analyst from Nordea Bank (OTCQX:NRDBY [https://seekingalpha.com/symbol/NRDBY]) (OTCQX:NBNKF [https://seekingalpha.com/symbol/NBNKF]) who has consistently issued bullish ratings on the drugmaker for over a decade.

Novod, who has worked at the Finnish bank for nearly 15 years across various roles, including as head of equity research in Denmark, will join the company as [https://www.bloomberg.com/news/articles/2025-10-23/novo-gives-top-ir-job-to-analyst-with-15-years-of-buy-ratings] senior vice president no later than May 1, 2026, Novo (OTCPK:NONOF [https://seekingalpha.com/symbol/NONOF]) said in a statement on Thursday.

“When this very interesting opportunity arose at Novo Nordisk, a company I have followed closely for most of my time as an equity analyst, I decided to make a change," Novod said.

According to Bloomberg data, since he began his coverage on Novo (NVO [https://seekingalpha.com/symbol/NVO]) in early 2011, Novod has reaffirmed Buy or Strong Buy ratings on the Wegovy maker except for a two-and-a-half-month period in 2016 when he downgraded the stock to Hold.

His recruitment comes at a time when the Danish drugmaker is going through [https://www.di.se/nyheter/di-avslojar-en-av-nordeas-tyngsta-analytiker-lamnar-for-novo-nordisk/] multiple leadership changes.

In August, the company named Maziar Mike Doustdar, its executive vice president of International Operations, as its new CEO. [https://seekingalpha.com/news/4473239-novo-nordisk-stock-drops-guidance-cut] On Wednesday, Novo (NVO [https://seekingalpha.com/symbol/NVO]) announced a major shakeup in its board of directors, proposing to appoint a new chair and vice chair at an extraordinary general meeting of shareholders scheduled for next month. [https://seekingalpha.com/news/4506071-novo-nordisk-chairman-others-quit-board-following-dispute-largest-shareholder]

MORE ON NOVO NORDISK

* Extraordinary General Meeting Conference Call [https://seekingalpha.com/article/4831540-extraordinary-general-meeting-conference-call]
* Novo Nordisk A/S (NVO) Discusses Extraordinary General Meeting on Proposed Board Changes and Governance Transcript [https://seekingalpha.com/article/4831459-novo-nordisk-a-s-nvo-discusses-extraordinary-general-meeting-on-proposed-board-changes-and]
* Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From [https://seekingalpha.com/article/4831488-eli-lilly-vs-novo-nordisk-one-to-walk-away-from-and-one-to-run-away-from]
* Trump administration prepares probe targeting global drug pricing — FT [https://seekingalpha.com/news/4506494-trump-administration-prepares-probe-targeting-global-drug-pricing-ft]
* Novo Nordisk chairman, others to quit board following dispute with largest shareholder [https://seekingalpha.com/news/4506071-novo-nordisk-chairman-others-quit-board-following-dispute-largest-shareholder]